Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Enochian Biosciences Inc    ENOB

ENOCHIAN BIOSCIENCES INC (ENOB)
My previous session
Most popular
Delayed Quote. Delayed  - 01/18 01:06:46 pm
8.06 USD   -5.18%
SummaryQuotesChartsNewsCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news

ENOCHIAN BIOSCIENCES INC : Change in Directors or Principal Officers (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 05:36pm EST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective January 7, 2018, Enochian Biosciences, Inc. (the "Company"), hired Luisa Puche as its full-time Chief Financial Officer to support the Company's growth as an exchange listed Company.

Ms. Puche, aged 55, has worked as a senior accounting and financial advisor and as President of Puche Group, LLC, an audit, regulatory, and corporate advisory consultancy, since 2015. Between 2010 and 2014, Ms. Puche served in various senior executive roles at Brightstar Corp., a global wireless device services provider, including as Vice President and Global Controller and as Interim Chief Accounting Officer. Ms. Puche also previously worked at Ernst and Young, most recently as Associate Director of the Security & Technology Solutions Consulting Practice from 200 through 2004. Ms. Puche holds a BS in Accounting from Florida International University.

In connection with her employment as Chief Financial Officer, Ms. Puche will receive an annual salary of $200,000 and eligibility for a bonus, with a target of 40% of her annual salary. Ms. Puche will also be entitled to receive a grant of 60,000 stock options and 15,000 shares of restricted stock under the Company's 2014 Equity Incentive Plan, which will vest annually over three years.

Other than the foregoing, there are no arrangements or understandings between Ms. Puche and any person (including the Company) pursuant to which Ms. Puche was appointed to serve as Chief Financial Officer, and there are no actual or proposed transactions between Ms. Puche or any of her related persons and the Company that would require disclosure under Item 404(a) of Regulation S-K in connection with her appointment as Chief Financial Officer.

Additionally, following the appointment of Ms. Puche, on January 9, 2019 the Company terminated the consulting agreement between its wholly-owned subsidiary Enochian BioSciences Denmark ApS and Crossfield, Inc. for the services of Robert Wolfe as part-time Chief Financial Officer of the Company.







  2

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ENOCHIAN BIOSCIENCES INC
01/11ENOCHIAN BIOSCIENCES INC : Change in Directors or Principal Officers (form 8-K)
AQ
01/08ENOCHIAN BIOSCIENCES : Announces Appointment of Dr. Mark Dybul as Executive Vice..
AQ
01/08ENOCHIAN BIOSCIENCES : Announces Appointment of Dr. Mark Dybul as Executive Vice..
AQ
01/07ENOCHIAN BIOSCIENCES INC : Change in Directors or Principal Officers, Amendments..
AQ
01/07ENOCHIAN BIOSCIENCES : Announces Appointment of Dr. Mark Dybul as Executive Vice..
AQ
More news
Chart ENOCHIAN BIOSCIENCES INC
Duration : Period :
Enochian Biosciences Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Rene Sindlev Chairman
Wenshi Wang Senior Vice President-Operations
Patricia Bettinger Senior Vice President-Research & Development
Henrik Gørnfeldt Sørensen Director
Mark Richard Dybul Executive Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ENOCHIAN BIOSCIENCES INC21.43%0
GILEAD SCIENCES9.75%88 807
VERTEX PHARMACEUTICALS12.33%48 689
REGENERON PHARMACEUTICALS11.75%44 377
GENMAB-1.73%9 846
SAREPTA THERAPEUTICS INC11.17%8 107